Cardiospermum

Heartseed Succeeds in Stable Production of High Purity Cardiomyocytes Using iPS Cells from I Peace, A Major Step Forward in Advancing Autologous Cardiac Regenerative Medicine

Retrieved on: 
Wednesday, November 1, 2023

As a result, Heartseed has successfully produced high-purity cardiomyocytes consistently from all iPS cell lines used in this study.

Key Points: 
  • As a result, Heartseed has successfully produced high-purity cardiomyocytes consistently from all iPS cell lines used in this study.
  • This achievement marks a significant step forward in the realization of autologous cardiac regenerative medicine, which uses iPS cells obtained from the patient's own cells.
  • However, the differentiation efficiency of iPS cells into target cells varies, and in order to efficiently produce cardiomyocytes from different donor-derived iPS cells, it is necessary to optimize the method of cardiomyocyte production for each iPS cell.
  • Heartseed and I Peace will continue to work towards establishing regenerative medicine using patients' own iPS cells.

Using iPS Cells from I Peace, Heartseed Succeeds in Stable Production of High Purity Cardiomyocytes, A Major Step Forward in Advancing Autologous Cardiac Regenerative Medicine

Retrieved on: 
Wednesday, November 1, 2023

This achievement marks a significant step forward in the realization of autologous cardiac regenerative medicine with I Peace's personal iPS cell banking service (My Peace), to manufacture and store iPS cells, and induce them into cardiomyocytes for use in autologous cell therapy.

Key Points: 
  • This achievement marks a significant step forward in the realization of autologous cardiac regenerative medicine with I Peace's personal iPS cell banking service (My Peace), to manufacture and store iPS cells, and induce them into cardiomyocytes for use in autologous cell therapy.
  • A major advantage of medical treatment using autologous iPS cells is that immunosuppressive agents are not necessary because no immune reaction occurs when cells are transplanted.
  • However, the differentiation efficiency of iPS cells into target cells varies, and to efficiently produce cardiomyocytes from different donor-derived iPS cells, it is necessary to optimize the method of cardiomyocyte production for each iPS cell.
  • I Peace will continue to work together with Heartseed towards establishing regenerative medicine for heart failures using patients' own iPS cells.

Heartseed raises 2 billion JPY in series D funding to accelerate development of iPSC-derived stem cell therapy for heart failure

Retrieved on: 
Thursday, May 25, 2023

Heartseed (Heartseed Inc.), a Tokyo-based biotechnology company developing iPSC-derived cardiomyocytes for heart failure (HF), today announced it has raised 2 billion JPY at Series D round, bringing its total financial backing to 10.2 billion JPY (approx.

Key Points: 
  • Heartseed (Heartseed Inc.), a Tokyo-based biotechnology company developing iPSC-derived cardiomyocytes for heart failure (HF), today announced it has raised 2 billion JPY at Series D round, bringing its total financial backing to 10.2 billion JPY (approx.
  • In addition, Heartseed will also examine a less invasive administration such as transendocardial injection using a catheter for global development by Novo Nordisk.
  • “The commitment from both new and existing investors in this round is a strong validation of our technology and strategic vision.
  • With their support, we look forward to accelerating our development to deliver potentially curative therapy for heart failure across the globe.”

Heartseed Raises $37 Million in Series C Funding to Accelerate Development of iPSC-derived Stem Cell Therapy for Heart Failure

Retrieved on: 
Friday, June 11, 2021

Heartseed , a Tokyo-based biotechnology company developing iPSC-derived cardiomyocytes for heart failure (HF), today announced it has raised 4 Billion-yen (approx.

Key Points: 
  • Heartseed , a Tokyo-based biotechnology company developing iPSC-derived cardiomyocytes for heart failure (HF), today announced it has raised 4 Billion-yen (approx.
  • $37 Million) at Series C round, bringing its total financial backing to 8.2 Billion yen (approx.
  • New investors are UTokyo Innovation Platform Co. (UTokyo IPC), Medical Incubator Japan, Keio Innovation Initiative (KII), and Sumitomo Mitsui Trust Investment.
  • With their support, we look forward to accelerating our development to deliver potentially curative therapy for heart failure across the globe.

Mutsuki Takano Was Appointed as CFO at Heartseed

Retrieved on: 
Tuesday, September 15, 2020

Heartseed Inc. (hereinafter Heartseed), a Tokyo-based biotechnology company developing iPSC-derived cardiomyocyte spheroids for the treatment of heart failure (HF), today announced that Mutsuki Takano has been appointed as Chief Financial Officer of Heartseed, effective September 14, 2020.

Key Points: 
  • Heartseed Inc. (hereinafter Heartseed), a Tokyo-based biotechnology company developing iPSC-derived cardiomyocyte spheroids for the treatment of heart failure (HF), today announced that Mutsuki Takano has been appointed as Chief Financial Officer of Heartseed, effective September 14, 2020.
  • Heartseed is also supporting an investigator-initiated clinical trial for HF led by Keio University.
  • Mutsuki Takano has total 16 years business experience, and joined Heartseed in August 2020.
  • I am privileged to work together for the company, said Mutsuki Takano.

Heartseed and ITOCHU CHEMICAL FRONTIER Sign Capital Alliance Agreement to Explore iPSC and Cardiomyocyte Business Opportunities

Retrieved on: 
Tuesday, March 10, 2020

In accordance with the partnership, ICF will invest in Heartseed in an extension round of its Series B financing.

Key Points: 
  • In accordance with the partnership, ICF will invest in Heartseed in an extension round of its Series B financing.
  • Through this partnership, Heartseed will leverage ICFs global network of academia and research institutions to explore iPS-Cell and Cardiomyocyte-related business opportunities.
  • US$26 million) in the Series B in November 2019 from SBI Investment, JMDC, Gene Techno Science, Nissay Capital, SMBC Venture Capital, and Astellas Venture Management LLC.
  • Heartseed has original technologies throughout the process of manufacturing and delivering iPSC-derived cardiac regenerative medicine, including purification, cell delivery and iPSC production.

Notice of Capital and Business Alliance Between Heartseed and MEDIPAL HOLDINGS

Retrieved on: 
Tuesday, March 10, 2020

Tokyo-based Heartseed Inc. (Heartseed), a Keio University-originated biotechnology company developing induced pluripotent stem cell (iPSC)-derived cardiac regenerative medicine, and MEDIPAL HOLDINGS CORPORATION (MEDIPAL) today announced that they have entered into a capital and business alliance.

Key Points: 
  • Tokyo-based Heartseed Inc. (Heartseed), a Keio University-originated biotechnology company developing induced pluripotent stem cell (iPSC)-derived cardiac regenerative medicine, and MEDIPAL HOLDINGS CORPORATION (MEDIPAL) today announced that they have entered into a capital and business alliance.
  • In conjunction with the alliance, MEDIPAL will acquire an equity stake in Heartseed.
  • In addition, MEDIPAL and its wholly owned subsidiary SPLine Corporation (SPLine) will begin collaborative research with Heartseed on the logistics of Heartseeds clinical trial supplies.
  • Heartseed is developing HS-001, allogeneic iPSC-derived cardiomyocyte spheroids for severe heart failure, which currently has no effective treatment other than heart transplantation.

Heartseed Raises $26M in Series B Funding to Accelerate Development of iPSC-derived Regenerative Medicine for Heart Failure

Retrieved on: 
Friday, November 22, 2019

Heartseed (Heartseed Inc.), a Tokyo-based biotechnology company developing iPSC-derived cardiomyocytes for the treatment of heart failure (HF), today announced it has raised 2.8 Billion-yen (approx.

Key Points: 
  • Heartseed (Heartseed Inc.), a Tokyo-based biotechnology company developing iPSC-derived cardiomyocytes for the treatment of heart failure (HF), today announced it has raised 2.8 Billion-yen (approx.
  • $26 Million) at Series B round, bringing its total financial backing to 3.8 Billion yen (approx.
  • Heartseed Inc. was founded in 2015 to develop and commercialize cardiac regenerative medicine developed by Prof. Keiichi Fukuda and his group at the Department of Cardiology, Keio University, Tokyo.
  • HS has original technologies throughout the process of manufacturing and delivering iPSC-derived cardiac regenerative medicine, including purification, cell delivery and iPSC production.